Summary & Overview

HCPCS G0431: Qualitative Multi-Class Drug Screen, High-Complexity

HCPCS Level II code G0431 represents a qualitative drug screen for multiple drug classes performed using high-complexity test methods such as immunoassay or enzyme assay, billed per patient encounter. This code is widely used for laboratory-based toxicology screening in outpatient clinics, emergency departments, and standalone laboratories. It matters nationally because standardized coding for multi-drug, high-complexity screens affects clinical workflows, laboratory reporting, and payer coverage decisions across public and private payers.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what this code captures, typical sites of service, and the clinical context for ordering multi-class high-complexity drug screens. The publication also summarizes benchmarking and policy-relevant considerations that often influence coverage and billing practices.

This report provides: a clear definition of the service captured by G0431; the clinical settings where the test is typically performed; common billing and coding implications; and areas where payers commonly set coverage criteria or prior authorization requirements. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG0431HCPCS Level IIdrug screentoxicologylaboratory servicesimmunoassayoutpatientbilling

Billing Code Overview

HCPCS Level II code G0431 describes a drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter. The service type is qualitative multi-class drug screening using high-complexity laboratory methods. The typical site of service is laboratory or outpatient clinical setting where high-complexity testing is performed, billed per patient encounter.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A patient presents to an outpatient addiction medicine clinic for routine monitoring of medication-assisted treatment and suspected nonadherence. The patient is a 38-year-old receiving buprenorphine for opioid use disorder who reports ongoing cravings. The clinician orders a point-of-care or clinic laboratory drug screen to assess recent use of opioids, benzodiazepines, amphetamines, cocaine, and other common substances. A phlebotomy technician collects a urine specimen during the same visit. The laboratory performs a qualitative, high-complexity immunoassay panel covering multiple drug classes, with results available the same day to guide treatment decisions. The clinic documents medical necessity, the encounter diagnosis (e.g., opioid use disorder), specimen source, and the time of collection. Billing uses HCPCS code G0431 for the high-complexity multiple drug class qualitative screen for that patient encounter. Modifier 26 may be appended when billing only the professional component is reported by the interpreting physician; modifier TC may be appended when billing only the technical component performed by the laboratory or facility. Typical sites of service include outpatient clinics, substance use disorder treatment programs, and hospital outpatient departments where laboratory immunoassay testing is performed.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when only the physician or qualified provider's interpretation/reporting portion is billed separately from the lab/facility technical component.
`TC`	Technical component	Use when only the laboratory or facility performs the specimen collection, processing, and testing and bills separately from the interpreting provider.
`59`	Distinct procedural service	Use when a separate, distinct laboratory procedure is performed on the same day that is not typically bundled with the drug screen.
`25`	Significant, separately identifiable evaluation and management service	Use when an E/M visit on the same day is medically necessary and distinct from the decision to perform the drug screen.
`91`	Repeat clinical diagnostic laboratory test	Use when the same drug screen is repeated on the same specimen or patient to confirm prior results within a short timeframe.
`QW`	CLIA waived test	Rarely applicable to `G0431` (high-complexity); do not use for high-complexity immunoassays — relevant when a waived point-of-care test is billed separately.
`KX`	Requirements specified in policy have been met	Use when payer-specific policy requires documentation of medical necessity and additional criteria are met for coverage.
`GA`	Waiver of liability statement on file (ABN)	Use when services are expected to be denied and the patient has signed an advanced beneficiary notice where required.
`GZ`	Item or service expected to be denied as not reasonable and necessary	Use when the provider documents the service as not reasonable and necessary and no ABN is on file.
`RE`	Replacement of prior service or item	Use when reprocessing or replacing a previously billed technical component due to testing error or specimen problem.

Taxonomy Code	Specialty	Notes
261QR0400X	Addiction Medicine	Common specialty ordering and interpreting drug screens for treatment monitoring.
207P00000X	Internal Medicine	Primary care physicians frequently order drug screens for chronic pain or medication monitoring.
2084P0800X	Medical Toxicology	Specialists interpret complex toxicology panels and confirm unexpected results.
207L00000X	Pathology-Laboratory	Laboratory directors and pathologists oversee high-complexity testing and reporting.
3336C0003X	Psychiatry & Neurology (Addiction Psychiatry)	Psychiatrists managing substance use disorders commonly order these screens.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F11.20`	Opioid dependence, uncomplicated	Common indication for ongoing toxicology monitoring while on medication-assisted treatment.
`F11.21`	Opioid dependence, in remission	Used when monitoring for relapse or confirming continued abstinence.
`F10.20`	Alcohol dependence, uncomplicated	Drug screens may be used in programs monitoring polydrug use including alcohol-related treatment contexts.
`F19.20`	Other psychoactive substance dependence, uncomplicated	Applies when multiple substances are suspected; supports multi-class drug screening.
`Z79.891`	Long term (current) use of opiate analgesic	Chronic opioid therapy monitoring in pain management often includes periodic drug screens.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81003`	Urinalysis, by dipstick or tablet reagent; non-automated, without microscopy	Often performed at or before specimen collection to assess urine validity and provide adjunct information.
`80305`	Drug test(s), presumptive, any number of drug classes; non-quantitative screen, multiple drug classes by high complexity test method	Alternative laboratory-level CPT for presumptive drug testing; similar clinical purpose when a CPT code is used instead of HCPCS.
`80307`	Drug test(s), presumptive, definitive, any number of drug classes; chromatographic method (eg, GC, LC), single drug class quantitative	Used when confirmatory or definitive testing by chromatography is required after a positive immunoassay screen.
`80310`	Drug test(s), definitive, qualitative or quantitative, multiple drug classes by mass spectrometry or chromatographic method	Used for confirmatory testing following a positive or unexpected `G0431` result; higher specificity than immunoassay.
`36415`	Collection of venous blood by venipuncture	If blood is required for confirmatory testing or additional toxicology assays, this CPT is billed for specimen collection.